Apnimed, Inc.
Apnimed is a clinical pharmaceutical company based in Cambridge, Massachusetts. It develops and manufactures oral therapies for sleep-related breathing diseases, focusing on their neurobiology. Its product AD109 is an oral treatment designed for obstructive sleep apnea that targets the neuromuscular dysfunction underlying the condition.
No enriched coverage for $APMD in the last 7 days.
No SEC Form 4 filings for $APMD in the last 30 days.
See all $APMD insider activity →Apnimed's NDA for AD109 (Oxnimbi) accepted by FDA, with a PDUFA target date of February 28, 2027. The once-daily oral therapy aims to treat obstructive sleep apnea, following two completed Phase 3 trials. The company raised $220.8 million in its July 2026 IPO.
Apnimed (APMD) announced five abstracts accepted for CHEST 2026, including late-breaking data on Phase 3 trials of AD109 for obstructive sleep apnea (OSA). The company will also host a panel discussion on trial results and their potential impact on OSA management. AD109's NDA is under FDA review with a PDUFA goal date of February 28, 2027.
Apnimed, Inc. (APMD) granted 19 employees stock options for 481,300 shares at $22.54 per share. The options vest over four years. The company is developing AD109, a drug for obstructive sleep apnea, with a PDUFA goal date of February 28, 2027. APMD believes AD109 could expand treatment options for OSA.
Recent APMD coverage spans regulation, financial news and insider activity.
Potential approval could drive significant upside for Apnimed.
Positive trial data could lift the stock as investors price in potential FDA approval.
The option grant introduces dilution risk and may modestly pressure the share price.
Positive regulatory milestone and strong earnings boost the company's valuation prospects.
The FDA timeline introduces uncertainty and potential upside if approval is granted, but also risk due to regulator concerns.
AlphAI scores every news story that mentions APMD with an AI model for sentiment and relevance, and aggregates insider trades from Apnimed, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Apnimed's NDA for AD109 (Oxnimbi) accepted by FDA, with a PDUFA target date of February 28, 2027. The once-daily oral therapy aims to treat obstructive sleep apnea, following two completed Phase 3 trials. The company raised $220.8 million in its July 2026 IPO.
Apnimed (APMD) announced five abstracts accepted for CHEST 2026, including late-breaking data on Phase 3 trials of AD109 for obstructive sleep apnea (OSA). The company will also host a panel discussion on trial results and their potential impact on OSA management. AD109's NDA is under FDA review with a PDUFA goal date of February 28, 2027.
Apnimed, Inc. (APMD) granted 19 employees stock options for 481,300 shares at $22.54 per share. The options vest over four years. The company is developing AD109, a drug for obstructive sleep apnea, with a PDUFA goal date of February 28, 2027. APMD believes AD109 could expand treatment options for OSA.
Apnimed, Inc. (APMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update • U.S. Food and Drug Administration (“FDA”) Accepted the NDA for AD109, with a proposed proprietary name Oxnimbi ™, and assigned a PDUFA target action date of February 28, 2027 • If approv
Apnimed's sleep apnea pill AD109 has a February 28, 2027, FDA decision date. The drug showed a 44.1% reduction in breathing interruptions in trials, but the FDA questioned its clinical meaningfulness. Apnimed (APMD) relies on this single product, and its future hinges on FDA approval.
Apnimed, Inc. (APMD) President Dennis Patrick Molnar reported an internal reclassification on Aug. 3, 2026, converting each Class A share into one Common share under SEC Rules 16b-7 and 16b-3. The filing also lists new stock option grants, including 55,596 options at a $16.00 exercise price granted July 30, 2026, vesting monthly over 24 months.
Morningside Venture Investments Ltd purchased 312,500 shares of Apnimed, Inc. (APMD) at $16.00 ($5.00M total) on 2026-08-03.
Apnimed, Inc. (Nasdaq: APMD) priced and closed an upsized Nasdaq IPO raising $220.8M in gross proceeds. It sold 13.8M shares at $16.00 each, including 1.8M from the underwriters’ overallotment option. Shares began trading July 31, 2026. The company develops AD109 for obstructive sleep apnea, with two Phase 3 trials completed and an NDA PDUFA goal date of Feb. 28, 2027.
SEKHRI PAUL J purchased 12,500 shares of Apnimed, Inc. (APMD) at $16.00 ($0.20M total) on 2026-08-03.
Apnimed raised $192M in its Nasdaq IPO, pricing 12M shares at $16 and debuting as APMD at $25, up 56% on the day. The company’s lead candidate Oxnimbi (formerly AD109) is under FDA review for obstructive sleep apnea. Apnimed submitted a new drug application in April; the FDA accepted it with a Feb. 28, 2027 decision date.
